Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine + gemcitabine/carboplatin versus carboplatin/etoposide in small cell lung cancer
2015-004170-15Phase 2Unknown
- Sponsor
- University College London
- Start
- Aug 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in small cell lung cancer (SCLC) comparing Hydroxychloroquine + gemcitabine + carboplatin with Carboplatin + etoposide (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
hydroxychloroquinegemcitabinecarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2015-004170-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004170-15.